Evidence map›Paper›PMID 42281889›Full record

ReviewOpen forum infectious diseases2026

Oluwafemi M Akinnurun, Roger Dumke

Abstract readReview
In one paragraph

Review in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Oluwafemi M AkinnurunTU Dresden, Institute of Medical Microbiology and Virology, Dresden, Germany.ORCID https://orcid.org/0000-0003-4310-0717
Roger DumkeTU Dresden, Institute of Medical Microbiology and Virology, Dresden, Germany.ORCID https://orcid.org/0000-0001-6351-8817

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: To summarize the current knowledge on Results: We included 70 studies with 207 patients. Various neurological manifestations were identified, affecting patients between the ages of 3 and 69. Cases of encephalitis predominated (72%). Diagnosis of Conclusions: While the administration of antibiotics is accepted for the treatment of CNS manifestations, the use of other therapies is guided by the severity of the course and empirical considerations.

Indexed as

CNS complicationsdiagnosisextrapulmonary manifestationsMycoplasma pneumoniaetreatment

Identifiers

PMID42281889
PMCPMC13251344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.